247 related articles for article (PubMed ID: 32241197)
1. Obeticholic acid for the treatment of nonalcoholic steatohepatitis.
Shah RA; Kowdley KV
Expert Rev Gastroenterol Hepatol; 2020 May; 14(5):311-321. PubMed ID: 32241197
[TBL] [Abstract][Full Text] [Related]
2. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
3. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
Ratziu V; Sanyal AJ; Loomba R; Rinella M; Harrison S; Anstee QM; Goodman Z; Bedossa P; MacConell L; Shringarpure R; Shah A; Younossi Z
Contemp Clin Trials; 2019 Sep; 84():105803. PubMed ID: 31260793
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
Makri E; Cholongitas E; Tziomalos K
World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
6. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
Loomba R; Sanyal AJ; Kowdley KV; Terrault N; Chalasani NP; Abdelmalek MF; McCullough AJ; Shringarpure R; Ferguson B; Lee L; Chen J; Liberman A; Shapiro D; Neuschwander-Tetri BA
Gastroenterology; 2019 Jan; 156(1):88-95.e5. PubMed ID: 30222962
[TBL] [Abstract][Full Text] [Related]
7. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
Adorini L; Pruzanski M; Shapiro D
Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
[TBL] [Abstract][Full Text] [Related]
8. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
9. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
Venetsanaki V; Karabouta Z; Polyzos SA
Eur J Pharmacol; 2019 Nov; 863():172661. PubMed ID: 31536725
[TBL] [Abstract][Full Text] [Related]
10. Current and new pharmacotherapy options for non-alcoholic steatohepatitis.
Sumida Y; Yoneda M; Ogawa Y; Yoneda M; Okanoue T; Nakajima A
Expert Opin Pharmacother; 2020 Jun; 21(8):953-967. PubMed ID: 32237916
[TBL] [Abstract][Full Text] [Related]
11. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
Siddiqui MS; Van Natta ML; Connelly MA; Vuppalanchi R; Neuschwander-Tetri BA; Tonascia J; Guy C; Loomba R; Dasarathy S; Wattacheril J; Chalasani N; Sanyal AJ;
J Hepatol; 2020 Jan; 72(1):25-33. PubMed ID: 31634532
[TBL] [Abstract][Full Text] [Related]
12. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.
Rodrigues PM; Afonso MB; Simão AL; Carvalho CC; Trindade A; Duarte A; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM; Castro RE
Cell Death Dis; 2017 Apr; 8(4):e2748. PubMed ID: 28406477
[TBL] [Abstract][Full Text] [Related]
13. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
[TBL] [Abstract][Full Text] [Related]
14. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
[TBL] [Abstract][Full Text] [Related]
15. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice.
Li J; Liu C; Zhou Z; Dou B; Huang J; Huang L; Zheng P; Fan S; Huang C
Phytother Res; 2021 Jun; 35(6):3351-3364. PubMed ID: 33784797
[TBL] [Abstract][Full Text] [Related]
16. Evolving Role for Pharmacotherapy in NAFLD/NASH.
Attia SL; Softic S; Mouzaki M
Clin Transl Sci; 2021 Jan; 14(1):11-19. PubMed ID: 32583961
[TBL] [Abstract][Full Text] [Related]
17. NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more?
Ray K
Nat Rev Gastroenterol Hepatol; 2015 Jan; 12(1):1. PubMed ID: 25421586
[No Abstract] [Full Text] [Related]
18. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
[TBL] [Abstract][Full Text] [Related]
19. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
[TBL] [Abstract][Full Text] [Related]
20. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]